Drug Interactions
Fluticasone propionate is a substrate of cytochrome P450 3A4. Coadministration of fluticasone propionate and the highly potent cytochrome P450 3A4 inhibitor ritonavir is not recommended based upon a multiple-dose, crossover drug interaction study in 18 healthy subjects.
Fluticasone propionate aqueous nasal spray (200 mcg once daily) was coadministered for 7 days with three P450 3A4 inhibitors: ritonavir (100 mg twice daily), ketoconazole (200 mg once daily), and erythromycin (500 mg twice daily). Coadministration with ritonavir resulted in a significant increase in plasma fluticasone propionate exposure and a significant decrease (86%) in plasma cortisol area under the plasma concentration versus time curve (AUC).
Coadministration with ketoconazole resulted in a slight increase in fluticasone propionate exposure and a 7% reduction in the area under the plasma cortisol AUC. Coadministration with erythromycin did not affect fluticasone propionate pharmacokinetics; there was a 2% reduction in the plasma cortisol AUC. Caution should be exercised when potent cytochrome P450 3A4 inhibitors (e. g., ketoconazole) are coadministered with fluticasone propionate
Pharmacodynamics
In a trial to evaluate the potential
